Predictors for Responsiveness to Corticosteroid in Patients With Early Acute Respiratory Distress Syndrome
Overview
In a recent multicenter randomized controlled trial, prolonged administration of low-dose methylprednisolone (1mg/kg/day) initiated in early acute respiratory distress syndrome was associated with earlier resolution of pulmonary and extrapulmonary organ dysfunction and reduction in duration of mechanical ventilation and intensive care unit stay. However, glucocorticoids may induce serious adverse events and these adverse events might compensate the positive effect of prolonged methylprednisolone infusion and discourage physicians from treating acute respiratory distress syndrome patients with glucocorticoids. Early prediction of responsiveness to prolonged methylprednisolone infusion would be help to decide whether to continue or not prolonged methylprednisolone infusion and this could reduce the drug related adverse events. We project to evaluate the predictors of responsiveness to prolonged methylprednisolone infusion in early acute respiratory distress syndrome .
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2011
Participating in This Clinical Trial
Inclusion Criteria
- AECC definition of acute respiratory distress syndrome – Early acute respiratory distress syndrome (within 72 h of diagnosis) – PF ratio < 200 at PEEP ≥ 8 cmH2O Exclusion Criteria:
- Imminent death – Contraindication to corticosteroid treatment – Already on more than 0.5 mg/kg of methylprednisolone or its equivalent – Evidence of uncontrolled infection – Refusal of managing physician to participate in the study
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Samsung Medical Center
- Provider of Information About this Clinical Study
- Principal Investigator: Gee Young Suh, Professor – Samsung Medical Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.